Delivery Order SPE2DR25D9225-SPE2DR26FFAZ0
- Not listed
- The Defense Logistics Agency awarded a $24,937.50 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Fasenra 30 mg/mL syringes. The delivery order, issued on November 24, 2025, with an ultimate completion date of November 25, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award falls under...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $24,435 to DMS Pharmaceutical Group Inc. for Fasenra 30 mg/ml syringes. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The delivery order is scheduled for completion by November 3, 2025, and represents one of numerous...
- The Defense Logistics Agency awarded a $19,950 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for FASENRA PEN 30 MG/ML. The award, issued on January 7, 2026, with an ultimate completion date of January 8, 2026, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. DMS Pharmaceutical Group is performing work at its Park Ridge facility and...
- The Defense Logistics Agency awarded a $9,975 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Fasenra Pen 30 mg/ml. The order, issued on January 7, 2026, with an ultimate completion date of January 8, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. Performance will occur at the contractor's...
- The Defense Logistics Agency issued a firm fixed-price delivery order valued at $4,987.52 to DMS Pharmaceutical Group Inc. for Fasenra Pen 30mg/ml, an injectable pharmaceutical product used in respiratory and immunological treatments. This delivery order, awarded on December 2, 2025, with an ultimate completion date of the same day, carries no set-aside designation and will be performed in Park Ridge, Illinois. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Fasenra Pen 30 mg/mL. The award, issued on January 5, 2026, with an ultimate completion date of January 6, 2026, utilizes firm fixed-price pricing with no set-aside designation, indicating the vendor competed in unrestricted federal procurement. DMS Pharmaceutical Group...
- The Defense Logistics Agency (DLA) awarded a $39,900 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Fasenra 30 mg/mL syringes. The award, issued on December 17, 2025, with a completion date of December 18, 2025, represents a firm fixed-price delivery order with no set-aside designation. This contract leverages DMS Pharmaceutical Group's position as a regional prime vendor under the DLA's Pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Fasenra Pen 30 mg/mL. The contract is a firm fixed-price delivery order with an ultimate completion date of January 7, 2026, and was issued without a set-aside designation. DMS Pharmaceutical Group is performing work at its headquarters location in Park Ridge, Illinois. This...
- The Defense Logistics Agency awarded a $2,493.75 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for FASENRA (benralizumab) 30 mg/mL pens. The award was issued on January 6, 2026, with an ultimate completion date of January 7, 2026, and carries no set-aside designation. This delivery order represents a routine procurement under DMS Pharmaceutical Group's broader Pharmaceutical Prime Vendor...
- The Defense Logistics Agency issued a delivery order valued at $14,962.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of FASENRA PEN 30 MG/ML. This firm fixed-price delivery order, awarded on January 5, 2026, with an ultimate completion date of January 6, 2026, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award...
- SPE2DR25D9225Indefinite Delivery Contract
- SPE2DR25D9225-SPE2DR26FFAZ0Delivery Order
The Defense Logistics Agency awarded a $9,975 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for Fasenra Pen 30 mg/ml on January 7, 2026. This delivery order, which carries no set-aside designation, is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The underlying PPV-G GEN V contract, valued at $499,999,999 and awarded in November 2025, is part of a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors supplying pharmaceuticals and medical consumables to Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group has demonstrated substantial contracting capability across the federal pharmaceutical supply chain, with recent delivery orders spanning oncology treatments, biologics, vaccines, and specialty pharmaceuticals. The company serves as a critical supplier for military healthcare operations under the PPV-G GEN V framework, which establishes firm fixed-price delivery orders for comprehensive pharmaceutical products including branded and generic prescription drugs, over-the-counter medications, and biologics to support recurring medical supply needs. With a completion date of January 8, 2026, this particular delivery order for the respiratory biologic Fasenra represents one of numerous pharmaceutical procurements the company fulfills to support Department of Defense medical operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.0k | 1/6/26 |